Rifampin-Induced Loss of Vilazodone Efficacy During Treatment of Pulmonary Tuberculosis

Patient Background

Mr. Daniel R. is a 46-year-old male with a history of major depressive disorder (MDD) that had remained in sustained remission for more than one year on vilazodone 40 mg once daily with food. He reported excellent adherence, good tolerability, and restoration of normal occupational and social functioning. He had experienced no recent depressive episodes and had required no antidepressant dose adjustments.

Daniel subsequently presented with a several-week history of persistent cough, night sweats, fatigue, reduced appetite, and unintentional weight loss. Chest imaging demonstrated an upper-lobe infiltrative process with cavitary changes. Sputum nucleic-acid amplification testing was positive for Mycobacterium tuberculosis, and subsequent susceptibility testing was consistent with drug-susceptible pulmonary tuberculosis.

He was commenced on standard initial antituberculous therapy with:

• Rifampin
• Isoniazid
• Pyrazinamide
• Ethambutol

His established vilazodone therapy was continued unchanged at 40 mg once daily.

Clinical Presentation

During the first several weeks of tuberculosis treatment, Daniel’s respiratory symptoms and constitutional features gradually improved. However, approximately four weeks after starting rifampin, he began experiencing a progressive deterioration in his mental health.

At follow-up, he reported:

• Persistent depressed mood
• Loss of interest in previously enjoyable activities
• Reduced motivation
• Increasing fatigue
• Difficulty concentrating
• Reduced social engagement

Daniel confirmed that he had continued taking vilazodone every day with food and denied missed doses. He reported no major new occupational, financial, interpersonal, or other psychosocial stressors. He also denied alcohol or recreational drug use.

Because fatigue, appetite disturbance, sleep changes, and reduced energy can occur with both tuberculosis and depression, the clinical team initially considered whether his symptoms represented residual effects of the infection. However, his tuberculosis symptoms were improving while his characteristic depressive symptoms—including anhedonia, low mood, and loss of motivation—were becoming progressively more prominent.

A comprehensive medication review was therefore undertaken.

Clinical Issue Identified

The pharmacist identified a clinically significant pharmacokinetic interaction between rifampin and vilazodone as a plausible contributor to the recurrence of Daniel’s depressive symptoms.

Vilazodone undergoes extensive hepatic metabolism, with CYP3A4 serving as its principal metabolic pathway. Rifampin is a potent inducer of CYP3A4. With repeated administration, rifampin increases the expression and activity of the enzyme, accelerating the metabolism of medications that depend on CYP3A4 for clearance.

The likely pharmacological sequence was:

Rifampin initiation → CYP3A4 induction → accelerated vilazodone metabolism → reduced systemic vilazodone exposure → diminished antidepressant effect → recurrence of depressive symptoms

The timing was particularly important. Daniel had remained clinically stable on vilazodone for more than one year, yet deterioration occurred several weeks after starting a strong enzyme inducer. This delayed onset is pharmacologically plausible because enzyme induction develops progressively rather than occurring immediately after the first rifampin dose.

The clinical presentation was therefore considered more consistent with reduced vilazodone exposure secondary to rifampin induction than with spontaneous failure of previously effective antidepressant therapy.

Pharmacist Intervention and Clinical Management

Confirm the nature and severity of the depressive relapse

Before modifying antidepressant therapy, Daniel should undergo a structured mental-health assessment, including evaluation of:

• Depressed mood and anhedonia
• Sleep and appetite
• Energy and concentration
• Occupational and social functioning
• Medication adherence
• Correct administration of vilazodone with food
• Suicidal ideation or self-harm risk
• Other medications or supplements capable of altering vilazodone exposure

A validated measure such as the PHQ-9 may be useful for documenting symptom severity and monitoring response over time.

Exclude other clinically relevant explanations

The healthcare team should avoid attributing the entire presentation automatically to the drug interaction.

Potential contributors should include:

• Active or incompletely treated tuberculosis
• Anaemia or other systemic illness
• Adverse effects of antituberculous medications
• Sleep disturbance
• Psychosocial consequences of a tuberculosis diagnosis
• Medication non-adherence
• A genuine recurrence of major depressive disorder independent of the interaction

In Daniel’s case, the combination of long-term previous psychiatric stability, verified adherence, improving tuberculosis symptoms, absence of major psychosocial changes, and the temporal relationship with rifampin initiation substantially increases the likelihood of a pharmacokinetic contribution.

Preserve effective tuberculosis treatment

Rifampin is a cornerstone of treatment for drug-susceptible pulmonary tuberculosis and should not be stopped solely because of the interaction without consultation with the tuberculosis or infectious-diseases team.

Management should therefore focus primarily on accommodating the interaction while maintaining an effective antituberculous regimen.

Consider temporary adjustment of vilazodone

For patients receiving a strong CYP3A4 inducer such as rifampin for more than 14 days, vilazodone prescribing information permits consideration of an increase in dosage according to clinical response.

Daniel’s vilazodone dose could therefore be gradually increased over approximately 1–2 weeks, with close monitoring, up to a maximum of 80 mg/day while strong CYP3A4 induction persists.

Dose escalation should not be automatic. The smallest adjustment necessary to restore clinical response should be used.

Monitor closely following dose adjustment

After any vilazodone dose modification, Daniel should be reviewed for:

• Improvement in mood and anhedonia
• Restoration of motivation and functioning
• Anxiety or agitation
• Gastrointestinal adverse effects
• Sleep disturbance
• Serotonergic adverse effects
• Emergence or worsening of suicidal thoughts
• Overall tolerability

Follow-up should occur sufficiently frequently to identify either continued treatment failure or excessive antidepressant exposure.

Plan prospectively for rifampin discontinuation

This represents a particularly important medication-safety step.

Once rifampin is discontinued, CYP3A4 induction does not disappear instantaneously but gradually resolves. As enzyme activity returns toward baseline, the same increased vilazodone dose could produce progressively greater systemic exposure.

If Daniel’s vilazodone dose had been increased during rifampin treatment, it should therefore be gradually returned toward his original 40-mg daily dose over approximately 1–2 weeks after the inducer is stopped, with continued assessment of antidepressant response and tolerability.

Failure to make this reverse adjustment could result in unnecessarily high vilazodone exposure after completion of rifampin therapy.

Coordinate care across specialties

The treatment plan should be communicated between:

• The tuberculosis/infectious-diseases team
• Primary care
• Psychiatry or mental-health services
• Pharmacy

The start and anticipated stop date of rifampin should be clearly documented so that both induction and de-induction phases are managed deliberately.

Clinical Rationale and Ramifications

This case demonstrates that an apparent relapse of depression may reflect a pharmacokinetic drug interaction rather than true antidepressant failure. Daniel had been stable on treatment before rifampin was introduced, making reduced antidepressant exposure a plausible explanation for the subsequent return of symptoms.

Failure to recognize this interaction could lead to unnecessary antidepressant switching, augmentation, additional psychotropic therapy, and greater adverse-effect burden. At the same time, rifampin is an essential component of tuberculosis treatment and should not be discontinued solely to avoid the interaction.

Management therefore requires balancing effective tuberculosis therapy with maintenance of adequate antidepressant exposure. When rifampin is eventually stopped, any antidepressant dose increase should also be reassessed because enzyme induction gradually resolves and drug concentrations may rise.

The delayed recurrence of depressive symptoms is also clinically important, as enzyme induction develops progressively over days to weeks. Recognizing this timeline helps distinguish a drug-exposure problem from genuine treatment resistance.